225 related articles for article (PubMed ID: 31369680)
1. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.
Furtner J; Genbrugge E; Gorlia T; Bendszus M; Nowosielski M; Golfinopoulos V; Weller M; van den Bent MJ; Wick W; Preusser M
Neuro Oncol; 2019 Dec; 21(12):1587-1594. PubMed ID: 31369680
[TBL] [Abstract][Full Text] [Related]
2. Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials.
Furtner J; Weller M; Weber M; Gorlia T; Nabors B; Reardon DA; Tonn JC; Stupp R; Preusser M;
Clin Cancer Res; 2022 Jan; 28(1):129-136. PubMed ID: 34667022
[TBL] [Abstract][Full Text] [Related]
3. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.
Furtner J; Berghoff AS; Albtoush OM; Woitek R; Asenbaum U; Prayer D; Widhalm G; Gatterbauer B; Dieckmann K; Birner P; Aretin B; Bartsch R; Zielinski CC; Schöpf V; Preusser M
Eur Radiol; 2017 Aug; 27(8):3167-3173. PubMed ID: 28050694
[TBL] [Abstract][Full Text] [Related]
4. Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma.
An G; Ahn S; Park JS; Jeun SS; Hong YK
J Cancer Res Clin Oncol; 2021 Mar; 147(3):901-909. PubMed ID: 32929611
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis.
Muglia R; Simonelli M; Pessina F; Morenghi E; Navarria P; Persico P; Lorenzi E; Dipasquale A; Grimaldi M; Scorsetti M; Santoro A; Politi LS
Eur Radiol; 2021 Jun; 31(6):4079-4086. PubMed ID: 33201284
[TBL] [Abstract][Full Text] [Related]
6. Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme?
Yesil Cinkir H; Colakoglu Er H
Asia Pac J Clin Oncol; 2020 Oct; 16(5):e223-e227. PubMed ID: 32762134
[TBL] [Abstract][Full Text] [Related]
7. A novel radiographic marker of sarcopenia with prognostic value in glioblastoma.
Huq S; Khalafallah AM; Ruiz-Cardozo MA; Botros D; Oliveira LAP; Dux H; White T; Jimenez AE; Gujar SK; Sair HI; Pillai JJ; Mukherjee D
Clin Neurol Neurosurg; 2021 Aug; 207():106782. PubMed ID: 34186275
[TBL] [Abstract][Full Text] [Related]
8. Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
Rulseh AM; Vymazal J
J Neurooncol; 2020 Jan; 146(1):157-162. PubMed ID: 31797235
[TBL] [Abstract][Full Text] [Related]
9. Temporalis muscle thickness as an indicator of sarcopenia predicts progression-free survival in head and neck squamous cell carcinoma.
Lee B; Bae YJ; Jeong WJ; Kim H; Choi BS; Kim JH
Sci Rep; 2021 Oct; 11(1):19717. PubMed ID: 34611230
[TBL] [Abstract][Full Text] [Related]
10. Temporal muscle thickness as an independent prognostic marker in glioblastoma patients-a systematic review and meta-analysis.
Sadhwani N; Aggarwal A; Mishra A; Garg K
Neurosurg Rev; 2022 Dec; 45(6):3619-3628. PubMed ID: 36350492
[TBL] [Abstract][Full Text] [Related]
11. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
Lupo JM; Essock-Burns E; Molinaro AM; Cha S; Chang SM; Butowski N; Nelson SJ
Neuro Oncol; 2013 Apr; 15(4):480-9. PubMed ID: 23393208
[TBL] [Abstract][Full Text] [Related]
12. Temporal muscle thickness as an independent prognostic imaging marker in newly diagnosed glioblastoma patients: A validation study.
Broen MPG; Beckers R; Willemsen ACH; Huijs SMH; Pasmans RCOS; Eekers DBP; Ackermans L; Beckervordersandforth J; van Raak EPM; Verduin M; Anten MHME; Hoeben A; Postma AA
Neurooncol Adv; 2022; 4(1):vdac038. PubMed ID: 35475275
[TBL] [Abstract][Full Text] [Related]
13. The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective.
Sütcüoğlu O; Erdal ZS; Akdoğan O; Çeltikçi E; Özdemir N; Özet A; Uçar M; Yazıcı O
Turk J Med Sci; 2023 Feb; 53(1):413-419. PubMed ID: 36945944
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of Temporal Muscle Thickness Measurements on Cranial Magnetic Resonance Images in the Prognosis of Patients With Primary Glioblastoma.
Liu F; Xing D; Zha Y; Wang L; Dong W; Li L; Gong W; Hu L
Front Neurol; 2020; 11():523292. PubMed ID: 33304303
[No Abstract] [Full Text] [Related]
15. Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases.
Furtner J; Berghoff AS; Schöpf V; Reumann R; Pascher B; Woitek R; Asenbaum U; Pelster S; Leitner J; Widhalm G; Gatterbauer B; Dieckmann K; Höller C; Prayer D; Preusser M
J Neurooncol; 2018 Oct; 140(1):173-178. PubMed ID: 30008154
[TBL] [Abstract][Full Text] [Related]
16. Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients.
Ten Cate C; Huijs SMH; Willemsen ACH; Pasmans RCOS; Eekers DBP; Zegers CML; Ackermans L; Beckervordersandforth J; van Raak EPM; Anten MHME; Hoeben A; Postma AA; Broen MPG
J Neurooncol; 2022 Dec; 160(3):611-618. PubMed ID: 36394717
[TBL] [Abstract][Full Text] [Related]
17. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF
Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562
[TBL] [Abstract][Full Text] [Related]
18. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models.
Kickingereder P; Burth S; Wick A; Götz M; Eidel O; Schlemmer HP; Maier-Hein KH; Wick W; Bendszus M; Radbruch A; Bonekamp D
Radiology; 2016 Sep; 280(3):880-9. PubMed ID: 27326665
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
20. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
